Neumora Therapeutics Reports Q4 Earnings Miss and Financial Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy NMRA?
Source: seekingalpha
- Earnings Report Miss: Neumora Therapeutics reported a Q4 GAAP EPS of -$0.35, missing expectations by $0.02, indicating challenges in profitability that could affect investor confidence.
- Cash Reserves Status: As of December 31, 2025, Neumora had cash and cash equivalents of $182.5 million, ensuring operational funding for the next two years, providing short-term financial stability despite profitability issues.
- Financial Guidance Outlook: The company expects its cash, cash equivalents, and marketable securities as of December 31, 2025, to fund its operating plan into Q3 2027, demonstrating a degree of foresight in financial management.
- Clinical Trial Progress: Neumora has achieved positive results in early-stage trials for NMRA-511 related to Alzheimer's disease, suggesting that despite poor financial performance, advancements in product development may drive future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NMRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NMRA
Wall Street analysts forecast NMRA stock price to rise
8 Analyst Rating
5 Buy
2 Hold
1 Sell
Moderate Buy
Current: 2.090
Low
3.00
Averages
9.33
High
18.00
Current: 2.090
Low
3.00
Averages
9.33
High
18.00
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Schall Law Firm Investigates Neumora Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Neumora Therapeutics, Inc. to determine if the company issued false or misleading statements that could affect investor rights.
- Legal Compliance Issues: The investigation focuses on whether Neumora failed to disclose information pertinent to investors, potentially leading to shareholder losses and impacting the company's reputation and future financing capabilities.
- Investor Rights Protection: Schall encourages affected shareholders to participate in the investigation and offers free legal consultations, aiming to help investors understand their rights and seek compensation.
- Securities Litigation Expertise: The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors worldwide, which underscores its professional capability and influence in protecting investor rights.
See More
Neumora Therapeutics Reports Positive Phase Ib Results for Alzheimer's Treatment
- Strong Financial Position: As of December 31, 2025, Neumora Therapeutics reported $182.5 million in cash and equivalents, expected to support operations into Q3 2027, demonstrating the company's financial resilience for ongoing R&D and market expansion.
- Clinical Trial Progress: The Phase Ib study of NMRA-511 showed clinically meaningful effects in Alzheimer's disease agitation with a favorable safety profile, potentially offering new hope for treatment options and enhancing the company's competitive edge in neuroscience.
- New Drug Development Updates: Neumora has fully enrolled participants for the KOASTAL-2 and KOASTAL-3 studies, with data expected in Q2 2026, which will provide critical support for the filing of navacaprant in major depressive disorder, further advancing its therapeutic applications.
- Challenges and Risks: Despite NMRA-215 showing leading weight loss data in a 12-week obesity study, unexpected adverse findings in a 13-week toxicology study have delayed clinical trials until Q1 2027, highlighting the challenges and uncertainties faced in drug development.
See More
Neumora Therapeutics Reports Q4 Earnings Miss and Financial Guidance
- Earnings Report Miss: Neumora Therapeutics reported a Q4 GAAP EPS of -$0.35, missing expectations by $0.02, indicating challenges in profitability that could affect investor confidence.
- Cash Reserves Status: As of December 31, 2025, Neumora had cash and cash equivalents of $182.5 million, ensuring operational funding for the next two years, providing short-term financial stability despite profitability issues.
- Financial Guidance Outlook: The company expects its cash, cash equivalents, and marketable securities as of December 31, 2025, to fund its operating plan into Q3 2027, demonstrating a degree of foresight in financial management.
- Clinical Trial Progress: Neumora has achieved positive results in early-stage trials for NMRA-511 related to Alzheimer's disease, suggesting that despite poor financial performance, advancements in product development may drive future growth.
See More
Schall Law Firm Investigates Neumora Therapeutics for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Neumora Therapeutics, focusing on potential violations of securities laws, which may involve false or misleading statements that could undermine investor confidence.
- Investor Rights: The investigation aims to protect shareholder rights and encourages affected investors to participate, indicating that the company faces legal risks that could negatively impact its stock price.
- Legal Expertise Support: Schall Law Firm specializes in securities class action lawsuits and offers free consultations, demonstrating its commitment and expertise in safeguarding investor rights.
- Potential Consequences: Should the investigation confirm violations by Neumora, the company may face significant legal liabilities, further affecting its market performance and investor trust.
See More
NMRA-511 Shows Promising Results in Alzheimer's Agitation
- Clinical Trial Results: NMRA-511 demonstrated a favorable safety profile in a Phase 1b study for Alzheimer's patients, with no somnolence or sedation, and significant improvements in agitation reflected by placebo-adjusted CMAI total score changes of -2.6 and -2.1 at Weeks 6 and 8, indicating its effectiveness in alleviating anxiety.
- Market Potential Forecast: William Blair projects peak U.S. sales of $1.8 billion for NMRA-511, viewing the early data as promising despite previous setbacks with the V1a receptor antagonist approach, suggesting a strong market outlook.
- Obesity Treatment Progress: Analyst Minter notes that positive Phase 2 data for NMRA-215 by year-end 2026 could represent a major inflection point for Neumora, with William Blair adding value to its model and modeling a 15% probability of success to unlock a greater than $2 billion market opportunity.
- Depression Asset Update: The KOASTAL-2/3 trials for monotherapy navacaprant in major depressive disorder are expected to read out in the second quarter of 2026, and while there is caution regarding its de-risking value, the update in the KOR antagonist space has intrigued investors.
See More
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
- FDA Approval: ScinoPharm Taiwan (TWSE:1789) received FDA approval for its Glatiramer Acetate Injection for treating adult multiple sclerosis patients, marking the company's first finished drug approval and paving the way for regulatory submissions in Europe and Asia for broader commercialization.
- Market Reaction: Following this announcement, ScinoPharm's stock price rose by 3.08% to NT$23.40 on January 8, 2025, reflecting positive market sentiment regarding the product's prospects.
- Clinical Trial Progress: The approval supports the company's competitiveness in the global market, as Glatiramer Acetate remains a key product despite revenue erosion from generics, highlighting its ongoing relevance in the biotech sector.
- Strategic Positioning: This approval not only strengthens ScinoPharm's position in the biopharmaceutical landscape but also lays the groundwork for future market expansions, demonstrating the company's commitment to innovative drug development.
See More
Schall Law Firm Investigates Neumora Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Neumora Therapeutics, Inc. to determine if the company issued false or misleading statements that could affect investor rights.
- Legal Compliance Issues: The investigation focuses on whether Neumora failed to disclose information pertinent to investors, potentially leading to shareholder losses and impacting the company's reputation and future financing capabilities.
- Investor Rights Protection: Schall encourages affected shareholders to participate in the investigation and offers free legal consultations, aiming to help investors understand their rights and seek compensation.
- Securities Litigation Expertise: The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors worldwide, which underscores its professional capability and influence in protecting investor rights.
See More
Neumora Therapeutics Reports Positive Phase Ib Results for Alzheimer's Treatment
- Strong Financial Position: As of December 31, 2025, Neumora Therapeutics reported $182.5 million in cash and equivalents, expected to support operations into Q3 2027, demonstrating the company's financial resilience for ongoing R&D and market expansion.
- Clinical Trial Progress: The Phase Ib study of NMRA-511 showed clinically meaningful effects in Alzheimer's disease agitation with a favorable safety profile, potentially offering new hope for treatment options and enhancing the company's competitive edge in neuroscience.
- New Drug Development Updates: Neumora has fully enrolled participants for the KOASTAL-2 and KOASTAL-3 studies, with data expected in Q2 2026, which will provide critical support for the filing of navacaprant in major depressive disorder, further advancing its therapeutic applications.
- Challenges and Risks: Despite NMRA-215 showing leading weight loss data in a 12-week obesity study, unexpected adverse findings in a 13-week toxicology study have delayed clinical trials until Q1 2027, highlighting the challenges and uncertainties faced in drug development.
See More
Neumora Therapeutics Reports Q4 Earnings Miss and Financial Guidance
- Earnings Report Miss: Neumora Therapeutics reported a Q4 GAAP EPS of -$0.35, missing expectations by $0.02, indicating challenges in profitability that could affect investor confidence.
- Cash Reserves Status: As of December 31, 2025, Neumora had cash and cash equivalents of $182.5 million, ensuring operational funding for the next two years, providing short-term financial stability despite profitability issues.
- Financial Guidance Outlook: The company expects its cash, cash equivalents, and marketable securities as of December 31, 2025, to fund its operating plan into Q3 2027, demonstrating a degree of foresight in financial management.
- Clinical Trial Progress: Neumora has achieved positive results in early-stage trials for NMRA-511 related to Alzheimer's disease, suggesting that despite poor financial performance, advancements in product development may drive future growth.
See More
Schall Law Firm Investigates Neumora Therapeutics for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Neumora Therapeutics, focusing on potential violations of securities laws, which may involve false or misleading statements that could undermine investor confidence.
- Investor Rights: The investigation aims to protect shareholder rights and encourages affected investors to participate, indicating that the company faces legal risks that could negatively impact its stock price.
- Legal Expertise Support: Schall Law Firm specializes in securities class action lawsuits and offers free consultations, demonstrating its commitment and expertise in safeguarding investor rights.
- Potential Consequences: Should the investigation confirm violations by Neumora, the company may face significant legal liabilities, further affecting its market performance and investor trust.
See More
NMRA-511 Shows Promising Results in Alzheimer's Agitation
- Clinical Trial Results: NMRA-511 demonstrated a favorable safety profile in a Phase 1b study for Alzheimer's patients, with no somnolence or sedation, and significant improvements in agitation reflected by placebo-adjusted CMAI total score changes of -2.6 and -2.1 at Weeks 6 and 8, indicating its effectiveness in alleviating anxiety.
- Market Potential Forecast: William Blair projects peak U.S. sales of $1.8 billion for NMRA-511, viewing the early data as promising despite previous setbacks with the V1a receptor antagonist approach, suggesting a strong market outlook.
- Obesity Treatment Progress: Analyst Minter notes that positive Phase 2 data for NMRA-215 by year-end 2026 could represent a major inflection point for Neumora, with William Blair adding value to its model and modeling a 15% probability of success to unlock a greater than $2 billion market opportunity.
- Depression Asset Update: The KOASTAL-2/3 trials for monotherapy navacaprant in major depressive disorder are expected to read out in the second quarter of 2026, and while there is caution regarding its de-risking value, the update in the KOR antagonist space has intrigued investors.
See More
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
- FDA Approval: ScinoPharm Taiwan (TWSE:1789) received FDA approval for its Glatiramer Acetate Injection for treating adult multiple sclerosis patients, marking the company's first finished drug approval and paving the way for regulatory submissions in Europe and Asia for broader commercialization.
- Market Reaction: Following this announcement, ScinoPharm's stock price rose by 3.08% to NT$23.40 on January 8, 2025, reflecting positive market sentiment regarding the product's prospects.
- Clinical Trial Progress: The approval supports the company's competitiveness in the global market, as Glatiramer Acetate remains a key product despite revenue erosion from generics, highlighting its ongoing relevance in the biotech sector.
- Strategic Positioning: This approval not only strengthens ScinoPharm's position in the biopharmaceutical landscape but also lays the groundwork for future market expansions, demonstrating the company's commitment to innovative drug development.
See More
